

Sporadic autism exomes reveal a highly interconnected protein network of *de novo* mutations

Brian J. O’Roak¹, Laura Vives¹, Santhosh Girirajan¹, Emre Karakoc¹, Niklas Krumm¹, Bradley P. Coe¹, Roie Levy¹, Arthur Ko¹, Choli Lee¹, Joshua D. Smith¹, Emily H. Turner¹, Ian B. Stanaway¹, Benjamin Vernot¹, Maika Malig¹, Carl Baker¹, Beau Reilly², Joshua M. Akey¹, Elhanan Borenstein^{1,3,4}, Mark J. Rieder¹, Deborah A. Nickerson¹, Raphael Bernier², Jay Shendure¹ & Evan E. Eichler^{1,5}

It is well established that autism spectrum disorders (ASD) have a strong genetic component; however, for at least 70% of cases, the underlying genetic cause is unknown¹. Under the hypothesis that *de novo* mutations underlie a substantial fraction of the risk for developing ASD in families with no previous history of ASD or related phenotypes—so-called sporadic or simplex families^{2,3}—we sequenced all coding regions of the genome (the exome) for parent–child trios exhibiting sporadic ASD, including 189 new trios and 20 that were previously reported⁴. Additionally, we also sequenced the exomes of 50 unaffected siblings corresponding to these new ($n = 31$) and previously reported trios ($n = 19$)⁴, for a total of 677 individual exomes from 209 families. Here we show that *de novo* point mutations are overwhelmingly paternal in origin (4:1 bias) and positively correlated with paternal age, consistent with the modest increased risk for children of older fathers to develop ASD⁵. Moreover, 39% (49 of 126) of the most severe or disruptive *de novo* mutations map to a highly interconnected β -catenin/chromatin remodelling protein network ranked significantly for autism candidate genes. In proband exomes, recurrent protein-altering mutations were observed in two genes: *CHD8* and *NTNG1*. Mutation screening of six candidate genes in 1,703 ASD probands identified additional *de novo*, protein-altering mutations in *GRIN2B*, *LAMC3* and *SCN1A*. Combined with copy number variant (CNV) data, these results indicate extreme locus heterogeneity but also provide a target for future discovery, diagnostics and therapeutics.

We selected 189 autism trios from the Simons Simplex Collection (SSC)⁶, which included males significantly impaired with autism and intellectual disability ($n = 47$), a female sample set ($n = 56$) of which 26 were cognitively impaired, and samples chosen at random from the remaining males in the collection ($n = 86$) (Supplementary Table 1 and Supplementary Fig. 1). In general, we excluded samples known to carry large *de novo* CNVs². Exome sequencing was performed as described previously⁴, but with an expanded target definition (see Methods). We achieved sufficient coverage for both parents and child to call genotypes for, on average, 29.5 megabases (Mb) of haploid exome coding sequence (Supplementary Table 1). In addition, we performed copy number analysis on 122 of these families, using a combination of the exome data, array comparative genomic hybridization (CGH), and genotyping arrays, thereby providing a more comprehensive view of rare variation.

In the 189 new probands, we validated 248 *de novo* events, 225 single nucleotide variants (SNVs), 17 small insertions/deletions (indels), and six CNVs (Supplementary Table 2). These included 181 non-synonymous changes, of which 120 were classified as severe based on sequence conservation and/or biochemical properties (Methods and Supplementary Table 3). The observed point mutation rate in coding sequence was ~ 1.3 events per trio or 2.17×10^{-8} per base

per generation, in close agreement with our previous observations⁴, yet in general, higher than previous studies, indicating increased sensitivity (Supplementary Table 2 and Supplementary Table 4)⁷. We also observed complex classes of *de novo* mutation including: five cases of multiple mutations in close proximity; two events consistent with paternal germline mosaicism (that is, where both siblings contained a *de novo* event observed in neither parent); and nine events showing a weak minor allele profile consistent with somatic mosaicism (Supplementary Table 3 and Supplementary Figs 2 and 3).

Of the severe *de novo* events, 28% (33 of 120) are predicted to truncate the protein. The distribution of synonymous, missense and nonsense changes corresponds well with a random mutation model⁷ (Supplementary Fig. 4 and Supplementary Table 2). However, the difference in nonsense rates between *de novo* and rare singleton events (not present in 1,779 other exomes) is striking (4:1) and suggests strong selection against new nonsense events (Fisher’s exact test, $P < 0.0001$). In contrast with a recent report⁸, we find no significant difference in mutation rate between affected and unaffected individuals; however, we do observe a trend towards increased non-synonymous rates in probands, consistent with the findings of ref. 9 (Supplementary Tables 1 and 2).

Given the association of ASD with increased paternal age⁵ and our previous observations⁴, we used molecular cloning, read-pair information, and obligate carrier status to identify informative markers linked to 51 *de novo* events and observed a marked paternal bias (41:10; binomial $P < 1.4 \times 10^{-5}$; Fig. 1a and Supplementary Tables 3 and 5). This provides strong direct evidence that the germline mutation rate in protein-coding regions is, on average, substantially higher in males. A similar finding was recently reported for *de novo* CNVs¹⁰. In addition, we observe that the number of *de novo* events is positively correlated with increasing paternal age (Spearman’s rank correlation = 0.19; $P < 0.008$; Fig. 1b). Together, these observations are consistent with the hypothesis that the modest increased risk for children of older fathers to develop ASD⁵ is the result of an increased mutation rate.

Using sequence read-depth methods in 122 of the 189 families, we scanned ASD probands for either *de novo* CNVs or rare ($< 1\%$ of controls), inherited CNVs. Individual events were validated by either array CGH or genotyping array (see Methods). We identified 76 events in 53 individuals, including six *de novo* (median size 467 kilobases (kb)) and 70 inherited (median size 155 kb) CNVs (Supplementary Table 6). These include disruptions of *EHT1* (Kleefstra’s syndrome, Online Mendelian Inheritance in Man (OMIM) accession 610253), *CNTNAP4* (reported in children with developmental delay and autism¹¹) and the 16p11.2 duplication (OMIM 611913) associated with developmental delay, bipolar disorder and schizophrenia.

We performed a multivariate analysis on non-verbal IQ (NVIQ), verbal IQ (VIQ) and the load of ‘extreme’ *de novo* mutations—where extreme is defined as point mutations that truncate proteins, intersect

¹Department of Genome Sciences, University of Washington School of Medicine, Seattle, Washington 98195, USA. ²Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington 98195, USA. ³Department of Computer Science and Engineering, University of Washington, Seattle, Washington 98195, USA. ⁴Santa Fe Institute, Santa Fe, New Mexico 87501, USA. ⁵Howard Hughes Medical Institute, Seattle, Washington 98195, USA.




Figure 1 | De novo mutation events in autism spectrum disorder.

a, Haplotype phasing using informative markers shows a strong parent-of-origin bias with 41 of 51 *de novo* events occurring on the paternally inherited haplotype. Arrows represent sequence reads from paternal (blue) or maternal (red) haplotypes. **b**, **c**, Box and whisker plots for 189 SSC probands. **b**, The paternal estimated age at conception versus the number of observed *de novo* point mutations (0, $n = 53$; 1, $n = 65$; 2, $n = 44$; 3+, $n = 27$). **c**, Decreased non-verbal IQ is significantly associated with an increasing number of extreme

mutation events (0, $n = 138$; 1, $n = 41$; 2+, $n = 10$), both with and without CNVs (Supplementary Discussion). **d**, Browser images showing CNVs identified in the del(18)(q12.2q21.1) syndrome region. The truncating point mutation in *SETBP1* occurs within the critical region, identifying the likely causative locus. Each red (deletion) and green (duplication) line represents an identified CNV in cases (solid lines) versus controls (dashed lines), with arrowheads showing point mutation.

Mendelian or ASD loci ($n = 57$), or *de novo* CNVs that intersect genes ($n = 5$) (Fig. 1c and Supplementary Discussion). NVIQ, but not VIQ, decreased significantly ($P < 0.01$) with increased number of events. Covariant analysis of the samples with CNV data showed that this finding was strengthened, but not exclusively driven, by the presence of either *de novo* or rare CNVs (Supplementary Fig. 5).

Among the *de novo* events, we identified 62 top ASD risk contributing mutations based on the deleteriousness of the mutations, functional evidence, or previous studies (Table 1). Probands with these mutations spanned the range of IQ scores, with only a modest non-significant trend towards individual's co-morbid with intellectual disability (Supplementary Figs 1 and 6). We observed recurrent, protein-disruptive mutations in two genes: *NTNG1* (netrin G1) and *CHD8* (chromodomain helicase DNA binding protein 8). Given their locus-specific mutation rates, the probability of identifying two independent mutations in our sample set is low (uncorrected, *NTNG1*: $P < 1.2 \times 10^{-6}$; *CHD8*: $P < 6.9 \times 10^{-5}$) (Supplementary Fig. 7, Supplementary Table 8 and Methods). *NTNG1* is a strong biological candidate given its role in laminar organization of dendrites and axonal guidance¹² and was also reported as being disrupted by a *de novo* translocation in a child with Rett's syndrome, without *MECP2* mutation¹³. Both *de novo* mutations identified here are missense (p.Tyr23Cys and p.Thr135Ile) at highly conserved positions predicted to disrupt protein function, although there is evidence of mosaicism for the former mutation (Supplementary Table 3).

CHD8 has not previously been associated with ASD and codes for an ATP-dependent chromatin-remodelling factor that has a significant role in the regulation of both β -catenin and p53 signalling^{14,15}. We also identified *de novo* missense variants in *CHD3* as well as *CHD7* (CHARGE syndrome, OMIM 214800), a known binding partner of *CHD8* (ref. 16). ASD has been found in as many as two-thirds of children with CHARGE, indicating that *CHD7* may contribute to an ASD syndromic subtype¹⁷.

We identified 30 protein-altering *de novo* events intersecting with Mendelian disease loci (Supplementary Table 3) as well as inherited hemizygous mutations of clinical significance (Supplementary Table 9).

The *de novo* mutations included truncating events in syndromic intellectual disability genes (*MBD5* (mental retardation, autosomal dominant 1, OMIM 156200), *RPS6KA3* (Coffin–Lowry syndrome, OMIM 303600) and *DYRK1A* (the Down's syndrome candidate gene, OMIM 600855)), and missense variants in loci associated with syndromic ASD, including *CHD7*, *PTEN* (macrocephaly/autism syndrome, OMIM 605309) and *TSC2* (tuberous sclerosis complex, OMIM 613254). Notably, *DYRK1A* is a highly conserved gene mapping to the Down's syndrome critical region (Supplementary Fig. 8). The proband here (13890) is severely cognitively impaired and microcephalic, consistent with previous studies of *DYRK1A* haploinsufficiency in both patients and mouse models¹⁸.

Twenty-one of the non-synonymous *de novo* mutations map to CNV regions recurrently identified in children with developmental delay and ASD (Supplementary Table 10), such as *MBD5* (2q23.1 deletion syndrome), *SYNRG* (17q12 deletion syndrome) and *POLRMT* (19p13.3 deletion)¹⁹. There is also considerable overlap with genes disrupted by single *de novo* CNVs in children with ASD (for example, *NLGN1* and *ARID1B*; Supplementary Table 11). Given the prior probability that these loci underlie genomic disorders, the disruptive *de novo* SNVs and small indels may be pinpointing the possible major effect locus for ASD-related features. For example, we identified a complex *de novo* mutation resulting in truncation of *SETBP1* (SET binding protein 1), one of five genes in the critical region for del(18)(q12.2q21.1) syndrome (Fig. 1d), which is characterized by hypotonia, expressive language delay, short stature and behavioural problems²⁰. Recurrent *de novo* missense mutations at *SETBP1* were recently reported to be causative for a distinct phenotype, Schinzel–Giedion syndrome, probably through a gain-of-function mechanism²¹, indicating diverse phenotypic outcomes at this locus depending on mutation mechanism.

Several of the mutated genes encode proteins that directly interact, suggesting a common biological pathway. From our full list of genes carrying truncating or severe missense mutations (126 events from all 209 families), we generated a protein–protein interaction (PPI) network based on a database of physical interactions (Supplementary Table 12)²². We found 39% (49 of 126) of the genes mapped to a highly

Table 1 | Top *de novo* ASD risk contributing mutations

Proband	NVIQ	Candidate gene	Amino acid change
12225.p1	89	<i>ABCA2</i>	p.Val1845Met
11653.p1	44	<i>ADCY5</i>	p.Arg603Cys
12130.p1	55	<i>ADNP</i>	Frameshift indel
11224.p1	112	<i>AP3B2</i>	p.Arg435His
13447.p1	51	<i>ARID1B</i>	Frameshift indel
13415.p1	48	<i>BRSK2</i>	3n indel
14292.p1	49	<i>BRWD1</i>	Frameshift indel
11872.p1	65	<i>CACNA1D</i>	p.Ala769Gly
11773.p1	50	<i>CACNA1E</i>	p.Gly1209Ser
13606.p1	60	<i>CDC42BPB</i>	p.Arg764TERM
12086.p1	108	<i>CDH5</i>	p.Arg545Trp
12630.p1	115	<i>CHD3</i>	p.Arg1818Trp
13733.p1	68	<i>CHD7</i>	p.Gly996Ser
13844.p1	34	<i>CHD8</i>	p.Gln959TERM
12752.p1	93	<i>CHD8</i>	Frameshift indel
13415.p1	48	<i>CNOT4</i>	p.Asp48Asn
12703.p1	58	<i>CTNNA1</i>	p.Thr551Met
11452.p1	80	<i>CUL3</i>	p.Glu246TERM
11571.p1	94	<i>CUL5</i>	p.Val355Ile
13890.p1	42	<i>DYRK1A</i>	Splice site
12741.p1	87	<i>EHD2</i>	p.Arg167Cys
11629.p1	67	<i>FBXO10</i>	p.Glu54Lys
13629.p1	63	<i>GPS1</i>	p.Arg492Gln
13757.p1	91	<i>GRINL1A</i>	3n indel
11184.p1	94	<i>HDGFRP2</i>	p.Glu83Lys
11610.p1	138	<i>HDLBP</i>	p.Ala639Ser
11872.p1	65	<i>KATNAL2</i>	Splice site
12346.p1	77	<i>MED5</i>	Frameshift indel
11947.p1	33	<i>MDM2</i>	p.Glu433Lys/p.Trp160TERM
11148.p1	82	<i>MLL3</i>	p.Tyr4691TERM
12157.p1	91	<i>NLGN1</i>	p.His795Tyr
11193.p1	138	<i>NOTCH3</i>	p.Gly1134Arg
11172.p1	60	<i>NR4A2</i>	p.Tyr275His
11660.p1	60	<i>NTNG1</i>	p.Thr135Ile
12532.p1	110	<i>NTNG1</i>	p.Tyr23Cys
11093.p1	91	<i>OPRL1</i>	p.Arg157Cys
13793.p1	56	<i>PCDH4</i>	p.Asp555His
11707.p1	23	<i>PDCD1</i>	Frameshift indel
12304.p1	83	<i>PSEN1</i>	p.Thr421Ile
11390.p1	77	<i>PTEN</i>	p.Thr167Asn
13629.p1	63	<i>PTPRK</i>	p.Arg784His
13333.p1	69	<i>RGMA</i>	p.Val379Ile
13222.p1	86	<i>RPS6KA3</i>	p.Ser369TERM
11257.p1	128	<i>RUVBL1</i>	p.Leu365Gln
11843.p1	113	<i>SES2</i>	p.Ala46Thr
12933.p1	41	<i>SETBP1</i>	Frameshift indel
12565.p1	79	<i>SETD2</i>	Frameshift indel
12335.p1	47	<i>TBL1XR1</i>	p.Leu282Pro
11480.p1	41	<i>TBR1</i>	Frameshift indel
11569.p1	67	<i>TNKS</i>	p.Arg568Thr
12621.p1	120	<i>TSC2</i>	p.Arg1580Trp
11291.p1	83	<i>TSPAN17</i>	p.Ser75TERM
11006.p1	125	<i>UBE3C</i>	p.Ser845Phe
12161.p1	95	<i>UBR3</i>	Frameshift indel
12521.p1	78	<i>USP15</i>	Frameshift indel
11526.p1	92	<i>ZBTB41</i>	p.Tyr886His
13335.p1	25	<i>ZNF420</i>	p.Leu76Pro

Proband	NVIQ	CNV Candidate gene	Type
11928.p1	66	<i>CHRNA7</i>	Duplication
13815.p1	56	<i>CNTNAP4</i>	Deletion
13726.p1	59	<i>CTNND1</i>	Deletion
12581.p1	34	<i>EHMT1</i>	Deletion
13335.p1	25	<i>TBX6</i>	Duplication

Top candidate mutations based on severity and/or supporting evidence from the literature.

interconnected network wherein 92% of gene pairs in the connected component are linked by paths of three or fewer edges (Fig. 2a). We tested this degree of interconnectivity by simulation ($n = 10,000$ replicates; Methods and Supplementary Fig. 9) and found that our experimental network had significantly more edges ($P < 0.0001$) and a greater clustering coefficient ($P < 0.0001$) than expected by chance.

To investigate the relevance of this network to autism further, we applied degree-aware disease gene prioritization (DADA)²³, based on the same PPI database to rank all genes based on their relatedness to a

set of 103 previously identified ASD genes¹⁷. We found that the genes with severe mutations ranked significantly higher than all other genes (Mann–Whitney U -test, $P < 4.0 \times 10^{-4}$), suggesting enrichment of ASD candidates. Furthermore, the 49 members of the connected component overwhelmingly drove this difference (Mann–Whitney U -test, $P < 1.6 \times 10^{-8}$), as the unconnected members were not significant on their own (Mann–Whitney U -test, $P < 0.28$), increasing our confidence that these connected gene products are probably related to ASD (Supplementary Fig. 10). Consistent with this finding, the rankings of unaffected sibling events are highly similar to the unconnected component, strengthening our confidence in the enrichment of the connected component of proband events for ASD-relevant genes.

Members of this network have known functions in β -catenin and p53 signalling, chromatin remodelling, ubiquitination and neuronal development (Fig. 2a). A fundamental developmental regulator observed in the network is *CTNNA1* (catenin (cadherin-associated protein), $\beta 1$, 88 kDa), also known as β -catenin. Interestingly, a parallel analysis using ingenuity pathway analysis (IPA) shows an enrichment of upstream interacting genes of the β -catenin pathway (8 of 358, $P = 0.0030$; see Methods, Supplementary Table 13 and Supplementary Fig. 11). A role for Wnt/ β -catenin signalling in ASD was previously proposed²⁴, largely on the basis of the association of common variants in *EN2* and *WNT2*, and the high rate of children with macrocephaly. It is striking that both individuals with *CHD8* mutations in this study have multiple *de novo* disruptive missense mutations in this pathway or closely related pathways (Fig. 2b, c and Supplementary Fig. 12) and both have macrocephaly.

In addition, the pathway analysis shows several other disrupted genes not identified in the PPI that are involved in common pathways, which in some cases are linked to β -catenin (Supplementary Discussion and Supplementary Fig. 11). *TBR1*, for example, is a transcription factor that has a critical role in the development of the cerebral cortex²⁵. *TBR1* binds with *CASK* and regulates several candidate genes for ASD and intellectual disability including *GRIN2B*, *AUTS2* and *RELN*—genes of recurrent ASD mutation, some of which are described here and in other studies^{4,9,11,17}.

Our exome analysis of *de novo* coding mutations in 209 autism trios identified only two recurrently altered genes, consistent with extreme locus heterogeneity underlying ASD. This extreme heterogeneity necessitates the analysis of very large cohorts for validation. We implemented a cost-effective approach based on molecular inversion probe (MIP) technology²⁶ for the targeted resequencing of six candidate genes in ~2,500 individuals, including 1,703 simplex ASD probands and 744 controls. Four of these candidates (*FOXP1*, *GRIN2B*, *LAMC3* and *SCN1A*) were identified previously⁴, whereas two (*FOXP2*, OMIM 602081 and *GRIN2A*, OMIM 613971) are related genes implicated in other neurodevelopmental phenotypes. We identified all previously observed *de novo* events (that is, in the same individuals), as well as additional *de novo* events in *GRIN2B* (two protein-truncating events), *SCN1A* (a missense) and *LAMC3* (a missense) (Supplementary Table 8). The observed number of *de novo* events was compared with expectations based on the mutation rates estimated for each gene (Methods and Supplementary Table 8), with *GRIN2B* showing the highest significance (uncorrected P value < 0.0002). Notably, the three *de novo* events observed in *GRIN2B* are all predicted to be protein truncating, whereas no events truncating *GRIN2B* were found in more than 3,000 controls (Methods).

Our analysis predicts extreme locus heterogeneity underlying the genetic aetiology of autism. Under a strict sporadic disorder-*de novo* mutation model, if 20–30% of our *de novo* point mutations are considered to be pathogenic, we can estimate between 384 and 821 loci (Methods and Supplementary Fig. 13). We reach a similar estimate if we consider recurrences from ref. 9. It is clear from phenotype and genotype data that there are many ‘autisms’ represented under the current umbrella of ASD and other genetic models are more likely in different contexts (for example, families with multiple affected




Figure 2 | Mutations identified in protein-protein interaction (PPI) networks. **a**, The 49-gene connected component of the PPI network formed from 126 genes with severe *de novo* mutations among the 209 probands.

b, Proband 13844 inherits three rare gene-disruptive CNVs and carries two *de novo* truncating mutations. **c**, GeneMANIA²² view of three of the affected genes (b) (red labels) which encode proteins that are part of a β -catenin-linked network. This proband is macrocephalic, impaired cognitively, and has deficits in social behaviour and language development (Supplementary Discussion).

individuals). There is marked convergence on genes previously implicated in intellectual disability and developmental delay. As has been noted for CNVs, this indicates that nosological divisions may not readily translate into differences at the molecular level. We believe that there is value in comparing mutation patterns in children with developmental delay (without features of autism) to those in children with ASD.

Although there is no one major genetic lesion responsible for ASD, it is still largely unknown whether there are subsets of individuals with a common or strongly related molecular aetiology and how large these subsets are likely to be. Using gene expression, protein-protein interactions, and CNV pathway analysis, recent reports have highlighted the role of synapse formation and maintenance^{27–29}. We find it intriguing that 49 proteins found to be mutated here have critical roles in fundamental developmental pathways, including β -catenin and p53 signalling, and that patients have been identified with multiple disruptive *de novo* mutations in interconnected pathways. The latter observations are consistent with an oligogenic model of autism where both *de novo* and extremely rare inherited SNV and CNV mutations contribute in conjunction to the overall genetic risk. Recent work has supported a role for these interconnected pathways in neuronal stem-cell fate-determination, differentiation and synaptic formation in humans and animal models^{24,30,31}. Given that fundamental developmental processes have previously been found to underlie syndromic forms of autism, a wider role of these pathways in idiopathic ASD would not be entirely surprising and would help explain the extreme genetic heterogeneity observed in this study.

METHODS SUMMARY

Exome capture, alignments and base-calling. Genomic DNA was derived directly from whole blood. Exomes were considered to be completed when ~90% of the capture target exceeded 8-fold coverage and ~80% exceeded 20-fold coverage. Exomes for the 189 trios (and 31 unaffected siblings) were captured with NimbleGen EZ Exome V2.0. Reads were mapped as in ref. 4 to a custom reference genome assembly (GRC build37). Genotypes were generated with GATK unified genotyper and parallel SAMtools pipeline⁴. Exomes for the unaffected siblings matching the pilot trios were captured and analysed as in ref. 4. Predicted *de novo* events were called as in ref. 4 and confirmed by capillary sequencing in all family members (for 176 of the 189 trios, this also included one unaffected sibling). Mutations were considered severe if they were truncating, missense with Grantham score ≥ 50 and GERP score ≥ 3 or only Grantham score ≥ 85 , or deleted a highly conserved amino acid.

Exome read-depth CNV analysis. Reads were mapped using mrsFAST and normalized reads per kilobase of exon per million mapped reads (RPKM) values

calculated by exon. Population normalization was performed using a set of 366 non-ASD exomes. Calls were made if three or more exons passed a threshold value and cross-validated calls using two orthogonal platforms, custom array CGH and Illumina 1M array data². CNVs were filtered to identify *de novo* and rare inherited events by comparison with 2,090 controls and 1,651 parent profiles.

Network reconstruction and null model estimation. PPI networks were generated using physical interaction data from GeneMANIA²². Null models were estimated using gene-specific mutation rate estimates based on human-chimp divergence. To rank candidate genes we obtained the seed ASD list from ref. 17 and severe disruptive *de novo* events from all families ($n = 209$). Given the PPI network and seed gene product list, we used DADA²³ for ranking each gene.

Human subjects. All samples and phenotypic data were collected under the direction of the Simons Simplex Collection by its 12 research clinic sites (<http://sfari.org/sfari-initiatives/simons-simplex-collection>). Parents consented and children assented as required by each local institutional review board. Participants were de-identified before distribution. Research was approved by the University of Washington Human Subject Division under non-identifiable biological specimens/data.

Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.

Received 8 September 2011; accepted 23 February 2012.

Published online 4 April 2012.

- Schaaf, C. P. & Zoghbi, H. Y. Solving the autism puzzle a few pieces at a time. *Neuron* **70**, 806–808 (2011).
- Sanders, S. J. *et al.* Multiple recurrent *de novo* CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. *Neuron* **70**, 863–885 (2011).
- Levy, D. *et al.* Rare *de novo* and transmitted copy-number variation in autistic spectrum disorders. *Neuron* **70**, 886–897 (2011).
- O’Roak, B. J. *et al.* Exome sequencing in sporadic autism spectrum disorders identifies severe *de novo* mutations. *Nature Genet.* **43**, 585–589 (2011).
- Hultman, C. M., Sandin, S., Levine, S. Z., Lichtenstein, P. & Reichenberg, A. Advancing paternal age and risk of autism: new evidence from a population-based study and a meta-analysis of epidemiological studies. *Mol. Psychiatry* **16**, 1203–1212 (2010).
- Fischbach, G. D. & Lord, C. The Simons Simplex Collection: a resource for identification of autism genetic risk factors. *Neuron* **68**, 192–195 (2010).
- Lynch, M. Rate, molecular spectrum, and consequences of human mutation. *Proc. Natl Acad. Sci. USA* **107**, 961–968 (2010).
- Xu, B. *et al.* Exome sequencing supports a *de novo* mutational paradigm for schizophrenia. *Nature Genet.* **43**, 864–868 (2011).
- Sanders, S. J. *et al.* *De novo* mutations revealed by whole-exome sequencing are strongly associated with autism. *Nature* <http://dx.doi.org/10.1038/nature10945> (this issue).
- Behr-Kwa, J. Y. *et al.* *De novo* copy number variants associated with intellectual disability have a paternal origin and age bias. *J. Med. Genet.* **48**, 776–778 (2011).
- O’Roak, B. J. & State, M. W. Autism genetics: strategies, challenges, and opportunities. *Autism Res.* **1**, 4–17 (2008).

12. Nishimura-Akiyoshi, S., Niimi, K., Nakashiba, T. & Itohara, S. Axonal netrin-Gs transneurally determine lamina-specific subdendritic segments. *Proc. Natl Acad. Sci. USA* **104**, 14801–14806 (2007).
13. Borg, I. *et al.* Disruption of Netrin G1 by a balanced chromosome translocation in a girl with Rett syndrome. *Eur. J. Hum. Genet.* **13**, 921–927 (2005).
14. Nishiyama, M. *et al.* CHD8 suppresses p53-mediated apoptosis through histone H1 recruitment during early embryogenesis. *Nature Cell Biol.* **11**, 172–182 (2009).
15. Thompson, B. A., Tremblay, V., Lin, G. & Bochar, D. A. CHD8 is an ATP-dependent chromatin remodeling factor that regulates β -catenin target genes. *Mol. Cell. Biol.* **28**, 3894–3904 (2008).
16. Batsukh, T. *et al.* CHD8 interacts with CHD7, a protein which is mutated in CHARGE syndrome. *Hum. Mol. Genet.* **19**, 2858–2866 (2010).
17. Betancur, C. Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting. *Brain Res.* **1380**, 42–77 (2011).
18. Moller, R. S. *et al.* Truncation of the Down syndrome candidate gene *DYRK1A* in two unrelated patients with microcephaly. *Am. J. Hum. Genet.* **82**, 1165–1170 (2008).
19. Cooper, G. M. *et al.* A copy number variation morbidity map of developmental delay. *Nature Genet.* **43**, 838–846 (2011).
20. Buysse, K. *et al.* Delineation of a critical region on chromosome 18 for the del(18)(q12.2q21.1) syndrome. *Am. J. Med. Genet. A* **146A**, 1330–1334 (2008).
21. Hoischen, A. *et al.* *De novo* mutations of SETBP1 cause Schinzel-Giedion syndrome. *Nature Genet.* **42**, 483–485 (2010).
22. Warde-Farley, D. *et al.* The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. *Nucleic Acids Res.* **38**, W214–W220 (2010).
23. Erten, S., Bebek, G., Ewing, R. & Koyutürk, M. DADA: Degree-aware algorithms for network-based disease gene prioritization. *BioData Mining* **4**, 19 (2011).
24. De Ferrari, G. V. & Moon, R. T. The ups and downs of Wnt signaling in prevalent neurological disorders. *Oncogene* **25**, 7545–7553 (2006).
25. Bedogni, F. *et al.* Tbr1 regulates regional and laminar identity of postmitotic neurons in developing neocortex. *Proc. Natl Acad. Sci. USA* **107**, 13129–13134 (2010).
26. Turner, E. H., Lee, C., Ng, S. B., Nickerson, D. A. & Shendure, J. Massively parallel exon capture and library-free resequencing across 16 genomes. *Nature Methods* **6**, 315–316 (2009).
27. Voineagu, I. *et al.* Transcriptomic analysis of autistic brain reveals convergent molecular pathology. *Nature* **474**, 380–384 (2011).
28. Sakai, Y. *et al.* Protein interactome reveals converging molecular pathways among autism disorders. *Sci. Transl. Med.* **3**, 86ra49 (2011).
29. Gilman, S. R. *et al.* Rare *de novo* variants associated with autism implicate a large functional network of genes involved in formation and function of synapses. *Neuron* **70**, 898–907 (2011).
30. Ille, F. & Sommer, L. Wnt signaling: multiple functions in neural development. *Cell. Mol. Life Sci.* **62**, 1100–1108 (2005).
31. Tedeschi, A. & Di Giovanni, S. The non-apoptotic role of p53 in neuronal biology: enlightening the dark side of the moon. *EMBO Rep.* **10**, 576–583 (2009).

Supplementary Information is linked to the online version of the paper at www.nature.com/nature.

Acknowledgements We would like to thank and recognize the following ongoing studies that produced and provided exome variant calls for comparison: NHLBI Lung Cohort Sequencing Project (HL 1029230), NHLBI WHI Sequencing Project (HL 102924), NIEHS SNPs (HHSN273200800010C), NHLBI/NHGRI SeattleSeq (HL 094976), and the Northwest Genomics Center (HL 102926). We are grateful to all of the families at the participating Simons Simplex Collection (SSC) sites, as well as the principal investigators (A. Beaudet, R. Bernier, J. Constantino, E. Cook, E. Fombonne, D. Geschwind, E. Hanson, D. Grice, A. Klin, R. Kochel, D. Ledbetter, C. Lord, C. Martin, D. Martin, R. Maxim, J. Miles, O. Ousley, K. Pelphrey, B. Peterson, J. Piggot, C. Saulnier, M. State, W. Stone, J. Sutcliffe, C. Walsh, Z. Warren and E. Wijsman). We also acknowledge M. State and the Simons Simplex Collection Genetics Consortium for providing Illumina genotyping data, T. Lehner and the Autism Sequencing Consortium for providing an opportunity for pre-publication data exchange among the participating groups. We appreciate obtaining access to phenotypic data on SFARI Base. This work was supported by the Simons Foundation Autism Research Initiative (SFARI 137578 and 191889; E.E.E., J.S. and R.B.) and NIH HD065285 (E.E.E. and J.S.). E.B. is an Alfred P. Sloan Research Fellow. E.E.E. is an Investigator of the Howard Hughes Medical Institute.

Author Contributions E.E.E., J.S. and B.J.O. designed the study and drafted the manuscript. E.E.E. and J.S. supervised the study. R.B., B.R. and B.J.O. analysed the clinical information. R.B., L.V., S.G., E.K., N.K. and B.P.C. contributed to the manuscript. S.G., N.K., B.P.C., A.K., C.B., M.M. and L.V. generated and analysed CNV data. B.J.O. and L.V. performed MIP resequencing and mutation validations. I.B.S., E.H.T., B.J.O. and J.S. developed MIP protocol and analysis. B.V. and J.M.A. generated loci-specific mutation rate estimates. R.L. and E.B. performed PPI network analysis and simulations. E.K. performed DADA analysis. C.L. performed Illumina sequencing. J.D.S., I.B.S., E.H.T. and C.L. analysed sequence data. B.P.C. performed IPA analysis. B.J.O., E.K. and N.K. developed the *de novo* analysis pipelines and analysed sequence data. D.A.N., M.J.R., J.D.S. and E.H.T. supervised exome sequencing and primary analysis.

Author Information Access to the raw sequence reads can be found at the NCBI database of Genotypes and Phenotypes (dbGaP) and National Database for Autism Research under accession numbers phs000482.v1.p1 and NDARCOL0001878, respectively. Reprints and permissions information is available at www.nature.com/reprints. The authors declare competing financial interests: details accompany the full-text HTML version of the paper at www.nature.com/nature. Readers are welcome to comment on the online version of this article at www.nature.com/nature. Correspondence and requests for materials should be addressed to E.E.E. (eee@gs.washington.edu) or J.S. (shendure@uw.edu).

METHODS

Exome capture, alignments and base-calling. Exomes for the 189 trios (and 31 unaffected siblings) were captured with NimbleGen EZ Exome V2.0. Final libraries were then sequenced on either an Illumina GAIIX (paired- or single-end 76-bp reads) or HiSeq2000 (paired- or single-end 50-bp reads). Reads were mapped to a custom GRCh37/hg19 build using BWA 0.5.6 (ref. 32). Read qualities were recalibrated using GATK Table Recalibration 1.0.2905 (ref. 33). Picard-tools 1.14 was used to flag duplicate reads (<http://picard.sourceforge.net/>). GATK IndelRealigner 1.0.2905 was used to realign reads around insertion/deletion (indel) sites. Genotypes were generated with GATK Unified Genotyper³³ with FILTER = "QUAL \leq 50.0 || AB \geq 0.75 || HRun $>$ 3 || QD $<$ 5.0" and in parallel with the SAMtools pipeline as described previously⁴. Only positions with at least eightfold coverage were considered. All pilot sibling exomes were captured and analysed as described previously⁴. Predicted *de novo* events were called and compared against a set of 946 other exomes to remove recurrent artefacts and likely undercalled sites. Indels were also called with the GATK Unified Genotyper and SAMtools and filtered to those with at least 25% of reads showing a variant at a minimum depth of 8 \times . Mutations were phased using molecular cloning of PCR fragments, read-pair information, linked informative SNPs, and obligate carrier status. To identify rare private variants (singleton), the full variant list was compared against a larger set of 1,779 other exomes. Predicted *de novo* indels were also filtered against this larger set.

Sanger validations. All reported *de novo* events (exome or MIP capture) were validated by designing primers with BatchPrimer3 followed by PCR amplification and Sanger sequencing. We performed PCR reactions using 10 ng of DNA from father, mother, unaffected sibling (when available), and proband and performed Sanger capillary sequencing of the PCR product using forward and reverse primers. In some cases, one direction could not be assessed due to the presence of repeat elements or indels in close proximity to the mutation event.

Mutation candidate gene analysis. We examined whether each non-synonymous or CNV *de novo* event may be contributing to the aetiology of ASD by evaluating the likelihood deleteriousness of the change (GERP, Grantham score) and intersecting with known syndromic and non-syndromic candidate genes, CNV morbidity maps, and information in OMIM and PubMed. Mutations were considered severe if they were truncating, missense with Grantham score \geq 50 and GERP score \geq 3 or only Grantham score \geq 85, or deleted a highly conserved amino acid. For genes that had not previously been implicated in ASD, we gave priority to those with structural similarities to known candidate or strong evidence of neural function or development.

Exome read-depth CNV discovery. To find CNVs using exome read-depth data, we first mapped sequenced reads to the hg19 exome using the mrsFAST aligner³⁴. Next, we applied a novel method (N.K. *et al.*, manuscript in preparation), which uses normalized RPKM values³⁵ of the \sim 194,000 captured exons/sequences, subsequent population normalization using 366 exomes from the Exome Sequencing Project and singular value decomposition to remove systematic bias present within exome capture reactions. Rare CNVs were detected using a threshold cutoff of the normalized RPKM values, and we required at least three exons above our threshold in order to make a call. We made a total of 1,077 deletion or duplication calls in 366 individuals (range 0–14, median = 3, mean = 2.94).

CNV detection using array CGH. A custom-targeted 2 \times 400K Agilent chip with median probe spacing of 500 bp in the genomic hotspots flanked by segmental duplications or Alu repeats and probe spacing of 14 kb in the genomic backbone was designed. All experiments were performed according to the manufacturer's instructions using NA12878 as the female reference and NA18507 as the male reference (Coriell). Data analysis was performed following feature extraction using DNA analytics with ADM-2 setting. All CNV calls were visually inspected in the UCSC Genome Browser. CNV calls from probands were then intersected with those from parents and also with 377 controls recruited through NIMH Genetics Initiative^{36,37} and ClinSeq cohort³⁸ analysed on the same microarray platform. The NIMH set of controls were ascertained by the NIMH Genetics Initiative³⁶ through an online self-report based on the Composite International Diagnostic Instrument Short-Form (CIDI-SF)³⁷. Those who did not meet DSM-IV criteria for major depression, denied a history of bipolar disorder or psychosis, and reported exclusively European origins were included^{39,40}. Samples from the ClinSeq cohort were selected from a population representing a spectrum of atherosclerotic heart disease³⁸. *De novo* and inherited potential pathogenic CNVs were selected only if they intersected with RefSeq coding sequence and allowing for a frequency of $<$ 1% in the controls and $<$ 50% segmental duplication content.

Illumina array CNV calling. CNV calling was performed in hg18 as described previously⁴¹, using an HMM that incorporates both allele frequencies (BAF) and total intensity values (logR). In total, we generated CNV calls for 841 probands, 1,651 parents and 793 siblings including the samples reported recently². Of the 122

families selected for CNV comparisons in this study, calls were generated for 107 probands. Of these, both parents were profiled for 101 families and one parent was profiled for the remaining six families. In addition, at least one sibling was profiled for 99 of these families.

Independent of array CGH detection, to identify putatively pathogenic CNVs, we first compared our data to 2,090 control samples derived from the Wellcome Trust Case Control Consortium (WTCCC) National Blood Services Cohort^{19,42} and filtered all CNVs present in 1% (20) of WTCCC2 controls or 1% (16) of parents by 50% reciprocal overlap with matching copy number status. In addition, similar to the filtering criteria used for array CGH detection, we selected only CNVs that contained less than 50% segmental duplication and intersected with RefSeq coding sequence. To select putative *de novo* CNVs, we further required the CNV not to be present in family-matched parents and siblings. Additionally, we filtered CNVs present in $>$ 0.1% (2) of the full 1,651 parent set. To select potential, rare inherited events, we required the CNV be detected in a matched parent or sibling. Finally, we filtered the genes inside each CNV under the same criteria (to account for smaller or larger CNPs) and removed CNVs with no remaining genes.

CNV cross validation. High-confidence, cross-validated *de novo* and inherited CNVs were selected by identifying events detected by at least two of three methodologies. To account for the variable breakpoint definitions in array CGH, SNP arrays, and exome copy number profiles, we aligned the CNVs by at least one overlapping gene ID and reported each CNV region by its maximal outer boundaries. This identified six *de novo* and 70 rare inherited events for further study (Supplementary Table 6).

Ingenuity pathway analysis. Ingenuity pathway analysis (IPA) was performed to identify potential functional enrichments within both our PPI (49 genes) and overall set of 126 genes. RefSeq reference gene list was used as a background list for all analysis. To confirm our results pertaining to *CTNNT1* upstream enrichment, we simulated 10,000 random populations of 209 individuals using Poisson priors for each gene based on their estimated mutation rates (see below), with a global correction factor resulting in selecting a mean of 126 genes per population. We then used this simulation data to calculate the probability of observing eight direct upstream interactors of *CTNNT1* and determined that our data set is enriched for these genes with $P = 0.0030$.

Estimating locus-specific mutation rates. Human–chimpanzee alignments were downloaded from the UCSC Genome Browser (reference versions GRCh37 and panTro2, <http://hgdownload.cse.ucsc.edu/goldenPath/hg19/vsPanTro2/syntenicNet/>). The more conservative syntenicNet alignments were used (details in <http://hgdownload.cse.ucsc.edu/goldenPath/hg19/vsPanTro2/README.txt>). Gene definitions were downloaded from the UCSC Table Browser, from the RefSeq Genes track, and the refFlat table. Exons were extended by 2 bp, and overlapping exons were merged using BEDTools. Non-exonic sequence was not considered. For each gene, we extracted: (1) d = the number of differences between chimpanzee and human; and (2) n = the number of bases aligned. We assumed a divergence time between human and chimpanzee of 12 million years (Myr) and an average generation time of 25 years. We then calculated gene-specific mutation rates per site per generation: $r = (d/n)/(12 \text{ Myr}/25 \text{ years/generation})$. We calculated the probability of observing $X+$ events using the Poisson distribution defined by the number of chromosomes screened and the size of the coding region, including actual splice bases.

Network simulation and null model estimation. To generate a null distribution of gene mutations, *de novo* mutation rates were estimated from human–chimp mutation rates. A pseudocount of 2.0833×10^{-6} (the smallest calculated in the gene set) was applied to any exon with a mutation rate of zero. To create null gene sets, genes were drawn uniformly from this background distribution. Human protein–protein interaction data were collected from GeneMANIA²² on 29 August 2011. Only direct physical interactions from the *Homo sapiens* database were considered. The list comprises approximately 1.5 million physical interactions, gathered from 150 studies. A protein interaction network was created from each experimental and null gene set by drawing edges between genes with physical interactions reported in the GeneMANIA database. Qualitatively similar results were achieved by including only interactions supported by multiple independent data sources. For each network, clustering coefficient, centralization, average shortest path length, density, and heterogeneity were determined using Cytoscape⁴³ and Network Analyzer⁴⁴. Duplicate- and self-interactions were not considered in calculating network statistics.

Disease gene prioritization based on PPI networks. We applied degree-aware algorithms to rank a set of candidate genes with respect to a set of products of genes associated with ASD using human PPI networks. We used the integrated human PPI network data collected from GeneMANIA²² on 29 August 2011. The PPI network contains 12,007 proteins with \sim 1.5 million direct physical interactions associated with a reliability score. We obtain the seed proteins for the ASD from the list of ref. 17. For the candidate set we used 126 gene products from the severe

disruptive *de novo* events from the pilot autism project⁴ and the current study. Given the GeneMANIA PPI network and Betancur seed gene product list, we used DADA²³ for ranking the candidate genes. We emphasize that this ranking is not implying causality but rather relatedness to genes previously and independently associated with ASD. For testing the significance of this ranking, we rank all the gene products except the seed set using the same algorithm. On the basis of the ranking result, we applied a Mann–Whitney *U* rank sum test (one-tailed) on the candidate set compared to all the other genes.

MIP protocol. Each of 1,703 autism probands from the SSC collection and 744 controls from the NIMH collection was subjected to MIP-based multiplex capture of the six genes: *SCN1A*, *GRIN2B*, *GRIN2A*, *LAMC3*, *FOXP1* and *FOXP2*. For each library, 50 ng of DNA was used. Individually synthesized 70 mer MIPs ($n = 355$) were pooled and 5' phosphorylated with T4 PNK (NEB). Hybridization with MIPs, gap filling and ligation were performed in one step for 45–48 h at 60 °C, followed by an exonuclease treatment of 30 min at 37 °C, similar to ref. 45, with modifications for reduced MIP number (B.J.O. *et al.*, manuscript in preparation). Amplification of the library was performed by PCR using different barcoded primers for each library. Then barcoded libraries were pooled, purified using Agencourt AMPure XP and one lane of 101-bp paired-end reads was generated for each mega-pool (~384) on an Illumina HiSeq 2000 according to manufacturer's instructions. Raw reads were mapped to the genome as in ref. 4. MIP targeting arms were then removed and variants called using SAMtools⁴. A 25-fold coverage, with AB allele ratio <0.7, and quality 30 threshold was used for high-confident variant calling. Private (possible *de novo*) variants were identified by filtering against 1,779 other exomes. The parents of children with disruptive rare variants were then captured. Variants not seen or with low coverage in the parents were validated by Sanger capillary-based fluorescent sequencing. No truncating variants of *GRIN2B* were observed in the MIP sequenced controls or the Exome Variant Server ESP2500 release (NHLBI Exome Sequencing Project (ESP), Seattle, Washington, <http://evs.gs.washington.edu/EVS/>).

Estimating the number of autism loci. The gene-level specificity of exome sequencing enables the estimation of the number of recurrently mutated genes implicated in the genetic aetiology of sporadic ASD. This question can be reformulated as the 'unseen species problem' (see ref. 46 for review and ref. 2 for application to *de novo* CNVs discovered in autism), where genes with severe *de novo* events in probands are considered 'observed species', and binned by their frequency of appearance (that is, singletons, doubletons, etc.). We estimated the total number of genes implicated in autism (the total number of species) using several different estimators (implemented in the R package SPECIES, <http://www.jstatsoft.org/>), as well as the formula provided in ref. 2. This estimate depends on the number of singletons and twin pairs of genes observed in probands, as well as the fraction of *de novo* events believed to be pathogenic for autism, that is, single, disruptive events that can cause autism on their own. We assumed that both of our

recurrent severe *de novo* events (affecting *CHD8* and *NTNG1*) were pathogenic; these compose the entire set of twin pairs. The number of singletons is based on the estimated a priori fraction of the observed events that are pathogenic for autism. Across this sliding scale, the estimated number of loci is plotted in Supplementary Fig. 13. For example, using the estimator from ref. 47, if 20–50% of our *de novo* severe events are considered pathogenic, exome sequencing of a large number of additional samples would reveal between 182 and 992 pathogenic genes harbouring coding *de novo* point mutations (Supplementary Fig. 13); if all the observed severe *de novo* events in our experiment are included as pathogenic singletons, the number of implicated loci increases to more than 3,000.

32. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. *Bioinformatics* **25**, 1754–1760 (2009).
33. DePristo, M. A. *et al.* A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nature Genet.* **43** (2011).
34. Hach, F. *et al.* mrsFAST: a cache-oblivious algorithm for short-read mapping. *Nature Methods* **7**, 576–577 (2010).
35. Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L. & Wold, B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. *Nature Methods* **5**, 621–628 (2008).
36. Moldin, S. O. NIMH Human Genetics Initiative: 2003 update. *Am. J. Psychiatry* **160**, 621–622 (2003).
37. Kessler, R. C. & Ustun, T. B. The World Mental Health (WMH) survey initiative version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). *Int. J. Methods Psychiatr. Res.* **13**, 93–121 (2004).
38. Biesecker, L. G. *et al.* The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. *Genome Res.* **19**, 1665–1674 (2009).
39. Talati, A., Fyer, A. J. & Weissman, M. M. A comparison between screened NIMH and clinically interviewed control samples on neuroticism and extraversion. *Mol. Psychiatry* **13**, 122–130 (2008).
40. Baum, A. E. *et al.* A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. *Mol. Psychiatry* **13**, 197–207 (2008).
41. Itsara, A. *et al.* Population analysis of large copy number variants and hotspots of human genetic disease. *Am. J. Hum. Genet.* **84**, 148–161 (2009).
42. Craddock, N. *et al.* Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. *Nature* **464**, 713–720 (2010).
43. Smoot, M. E., Ono, K., Ruscheinski, J., Wang, P. L. & Ideker, T. Cytoscape 2.8: new features for data integration and network visualization. *Bioinformatics* **27**, 431–432 (2011).
44. Assenov, Y., Ramirez, F., Schelhorn, S. E., Lengauer, T. & Albrecht, M. Computing topological parameters of biological networks. *Bioinformatics* **24**, 282–284 (2008).
45. Mamanova, L. *et al.* Target-enrichment strategies for next-generation sequencing. *Nature Methods* **7**, 111–118 (2010).
46. Bunge, J. & Fitzpatrick, M. Estimating the number of species - a Review. *J. Am. Stat. Assoc.* **88**, 364–373 (1993).
47. Chao, A. & Lee, S. M. Estimating the number of classes via sample coverage. *J. Am. Stat. Assoc.* **87**, 210–217 (1992).